Literature DB >> 21255008

Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.

Anna Korniejewska1, Andrew J McKnight, Zoë Johnson, Malcolm L Watson, Stephen G Ward.   

Abstract

The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 are involved in variety of inflammatory disorders including multiple sclerosis, rheumatoid arthritis, psoriasis and sarcoidosis. Two alternatively spliced variants of the human CXCR3-A receptor have been described, termed CXCR3-B and CXCR3-alt. Human CXCR3-B binds CXCL9, CXCL10, CXCL11 as well as an additional ligand CXCL4. In contrast, CXCR3-alt only binds CXCL11. We report that CXCL4 induces intracellular calcium mobilization as well as Akt and p44/p42 extracellular signal-regulated kinase phosphorylation, in activated human T lymphocytes. These responses have similar concentration dependence and time-courses to those induced by established CXCR3 agonists. Moreover, phosphorylation of Akt and p44/p42 is inhibited by pertussis toxin, suggesting coupling to Gα(i) protein. Surprisingly, and in contrast with the other CXCR3 agonists, stimulation of T lymphocytes with CXCL4 failed to elicit migratory responses and did not lead to loss of surface CXCR3 expression. Taken together, our findings show that, although CXCL4 is coupled to downstream biochemical machinery, its role in T cells is probably distinct from that of CXCR3-A agonists.
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255008      PMCID: PMC3075504          DOI: 10.1111/j.1365-2567.2010.03384.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  60 in total

1.  Role of clathrin-mediated endocytosis in CXCR2 sequestration, resensitization, and signal transduction.

Authors:  W Yang; D Wang; A Richmond
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

2.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.

Authors:  S Qin; J B Rottman; P Myers; N Kassam; M Weinblatt; M Loetscher; A E Koch; B Moser; C R Mackay
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

3.  The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis.

Authors:  L Trentin; C Agostini; M Facco; F Piazza; A Perin; M Siviero; C Gurrieri; S Galvan; F Adami; R Zambello; G Semenzato
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

4.  Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling.

Authors:  R L Rabin; M K Park; F Liao; R Swofford; D Stephany; J M Farber
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

5.  Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells.

Authors:  F Mach; A Sauty; A S Iarossi; G K Sukhova; K Neote; P Libby; A D Luster
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

6.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients.

Authors:  T L Sørensen; M Tani; J Jensen; V Pierce; C Lucchinetti; V A Folcik; S Qin; J Rottman; F Sellebjerg; R M Strieter; J L Frederiksen; R M Ransohoff
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

7.  Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2. Evidence for time-dependent signal generation.

Authors:  R M Richardson; B C Pridgen; B Haribabu; H Ali; R Snyderman
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

8.  cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection.

Authors:  S W Cole; B D Jamieson; J A Zack
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

9.  Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization.

Authors:  M Loetscher; P Loetscher; N Brass; E Meese; B Moser
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

10.  Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.

Authors:  K E Cole; C A Strick; T J Paradis; K T Ogborne; M Loetscher; R P Gladue; W Lin; J G Boyd; B Moser; D E Wood; B G Sahagan; K Neote
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  42 in total

1.  'Neuroinflammation' differs categorically from inflammation: transcriptomes of Alzheimer's disease, Parkinson's disease, schizophrenia and inflammatory diseases compared.

Authors:  Michaela D Filiou; Ahmed Shamsul Arefin; Pablo Moscato; Manuel B Graeber
Journal:  Neurogenetics       Date:  2014-06-15       Impact factor: 2.660

Review 2.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

3.  Establishing Classification Tree Models in Rheumatoid Arthritis Using Combination of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry and Magnetic Beads.

Authors:  Dan Ma; Nana Liang; Liyun Zhang
Journal:  Front Med (Lausanne)       Date:  2021-02-24

4.  Activation of CXCL10/CXCR3 signaling attenuates morphine analgesia: involvement of Gi protein.

Authors:  Dawei Ye; Huilian Bu; Genhua Guo; Bin Shu; Wei Wang; Xuehai Guan; Hui Yang; Xuebi Tian; Hongbing Xiang; Feng Gao
Journal:  J Mol Neurosci       Date:  2014-01-12       Impact factor: 3.444

5.  Serum CXCL11 correlates with pulmonary outcomes and disease burden in sarcoidosis.

Authors:  Nicholas K Arger; Melissa Ho; Prescott G Woodruff; Laura L Koth
Journal:  Respir Med       Date:  2019-04-17       Impact factor: 3.415

6.  Inhibitors of DAG metabolism suppress CCR2 signalling in human monocytes.

Authors:  Priscilla Day; Lisa Burrows; David Richards; Samuel J Fountain
Journal:  Br J Pharmacol       Date:  2019-06-17       Impact factor: 8.739

7.  CXCL9 is important for recruiting immune T cells into the brain and inducing an accumulation of the T cells to the areas of tachyzoite proliferation to prevent reactivation of chronic cerebral infection with Toxoplasma gondii.

Authors:  Eri Ochiai; Qila Sa; Morgan Brogli; Tomoya Kudo; Xisheng Wang; Jitender P Dubey; Yasuhiro Suzuki
Journal:  Am J Pathol       Date:  2014-11-26       Impact factor: 4.307

Review 8.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

9.  Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil.

Authors:  Jing Gao; Jin Gao; Lan Qian; Xia Wang; Mingyuan Wu; Yang Zhang; Hao Ye; Shunying Zhu; Yan Yu; Wei Han
Journal:  Cancer Biol Ther       Date:  2014-05-06       Impact factor: 4.742

10.  Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.

Authors:  M R Pranzatelli; E D Tate; N R McGee; A L Travelstead; S J Verhulst; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.